MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited is a biopharmaceutical company dedicated to the global development and provision of plant-derived medicines. The firm manufactures and distributes both medical cannabis products and a range of non-cannabis botanical therapeutics. Among its key investigational drug candidates are CimetrA, which is undergoing Phase III clinical trials for the symptomatic treatment of early-stage COVID-19; CannEpil, a Phase IIb cannabis-based therapy targeting drug-resistant epilepsy; and CogniCann, currently in Phase II clinical evaluation for the symptomatic relief of dementia. Beyond its core pipeline, MGC Pharmaceuticals also offers its ArtemiC product line, various cannabinoid-focused items, and other non-pharmaceutical goods. The company further extends its services to include consulting, particularly in clinical research. Established in 2014 and headquartered in West Perth, Australia, the company previously operated as Erin Resources Limited before rebranding to MGC Pharmaceuticals Limited in December 2015.